Central acylated ghrelin improves memory function and hippocampal AMPK activation and partly reverses the impairment of energy and glucose metabolism in rats infused with β-amyloid

•Hippocampal β-amyloid deposition resulted in memory loss and impairment of energy and glucose metabolisms.•Rats administered central acyl-ghrelin, had less β-amyloid deposition in the hippocampus.•Central acyl-ghrelin prevented cognitive dysfunction in rats infused with β-amyloid.•Central acyl-ghre...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Peptides (New York, N.Y. : 1980) N.Y. : 1980), 2015-09, Vol.71, p.84-93
Hauptverfasser: Kang, Suna, Moon, Na Rang, Kim, Da Sol, Kim, Sung Hoon, Park, Sunmin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Hippocampal β-amyloid deposition resulted in memory loss and impairment of energy and glucose metabolisms.•Rats administered central acyl-ghrelin, had less β-amyloid deposition in the hippocampus.•Central acyl-ghrelin prevented cognitive dysfunction in rats infused with β-amyloid.•Central acyl-ghrelin suppressed the deterioration of energy and glucose metabolism.•Elevating acyl-ghrelin, possibly by intermittent fasting, may improve cognitive function. Ghrelin is a gastric hormone released during the fasting state that targets the hypothalamus where it induces hunger; however, emerging evidence suggests it may also affect memory function. We examined the effect of central acylated-ghrelin and DES-acetylated ghrelin (native ghrelin) on memory function and glucose metabolism in an experimentally induced Alzheimer’s disease (AD) rat model. AD rats were divided into 3 groups and Non-AD rats were used as a normal-control group. Each rat in the AD groups had intracerebroventricular (ICV) infusion of β-amyloid (25–35; 16.8nmol/day) into the lateral ventricle for 3 days, and then the pumps were changed to infuse either acylated-ghrelin (0.2nmol/h; AD-G), DES-acylated ghrelin (0.2nmol/h; AD-DES-G), or saline (control; AD-C) for 3 weeks. The Non-AD group had ICV infusion of β-amyloid (35–25) which does not deposit in the hippocampus. During the next 3 weeks memory function, food intake, body weight gain, body fat composition, and glucose metabolism were measured. AD-C exhibited greater β-amyloid deposition compared to Non-AD-C, and AD-G suppressed the increased β-amyloid deposition and potentiated the phosphorylation AMPK. In addition, AD-G increased the phosphorylation GSK and decreased the phosphorylation of Tau in comparison to AD-C and AD-DES-G. Cognitive function, measured by passive avoidance and water maze tests, was much lower in AD-C than Non-AD-C whereas AD-G but not AD-DES-G prevented the decrease (p
ISSN:0196-9781
1873-5169
DOI:10.1016/j.peptides.2015.07.005